Guggenheim Starts Mineralys Therapeutics, Inc. (MLYS) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St on track for subdued September start as high yields, oil prices dent sentiment
- Oil up about 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
Stifel positive on Mineralys Therapeutics due to 'seemingly unlimited upside market'
March 7, 2023 10:55 AM ESTStifel analyst Annabel Samimy initiated a Buy rating and $45 per share price target on Mineralys Therapeutics (NASDAQ: MLYS) in a note to clients on Tuesday.
The analyst acknowledged that the hypertension market has been in "decades-long stasis, with the level of uncontrolled and... More
